Compare AWR & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AWR | LQDA |
|---|---|---|
| Founded | 1929 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.4B |
| IPO Year | 1998 | 2020 |
| Metric | AWR | LQDA |
|---|---|---|
| Price | $76.23 | $38.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $84.00 | $41.00 |
| AVG Volume (30 Days) | 259.5K | ★ 937.1K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.59% | N/A |
| EPS Growth | 6.31 | ★ 51.81 |
| EPS | ★ 3.37 | N/A |
| Revenue | ★ $658,073,000.00 | $158,320,000.00 |
| Revenue This Year | $5.20 | $278.87 |
| Revenue Next Year | $2.27 | $57.13 |
| P/E Ratio | $22.32 | ★ N/A |
| Revenue Growth | 10.52 | ★ 1031.18 |
| 52 Week Low | $69.45 | $11.85 |
| 52 Week High | $82.94 | $46.67 |
| Indicator | AWR | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 47.20 | 53.00 |
| Support Level | $71.21 | $35.00 |
| Resistance Level | $80.58 | $39.19 |
| Average True Range (ATR) | 1.88 | 1.82 |
| MACD | -0.40 | -0.03 |
| Stochastic Oscillator | 26.07 | 43.39 |
American States Water Co is a water and utilities holding company based in California. The segments of the firm include water, electric, and contracted services. Within these segments, American States Water conducts water and electric operations through Golden State Water Company and Bear Valley Electric Service, Inc while contracted services through American States Utility Services and its subsidiaries. Golden State Water conducts its operations across various counties in California and is regulated by the California Public Utilities Commission. American States Utility Services has contracted with the U.S. government to provide water services to various military installations. The majority of the company's revenue is derived from water services to commercial and residential customers.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.